Maxim upgrades Citius Oncology to Buy, sees its capital needs being met

Maxim upgraded Citius Oncology (CTOR) to Buy from Hold with a $6 price target The company has taken key steps to address its capital needs and now should have a path to launching Lymphir in Q4 of this year, which is a “key event” for Citius, the analyst tells investors in a research note. Cutaneous T-cell lymphoma is a relatively small and concentrated market, which should support pricing of about $300K per course of treatment, and the firm believes that sales could “ramp quickly” in 2026, the firm added.